Pfizer (PFE) Deferred Taxes (2009 - 2026)

Pfizer has disclosed Deferred Taxes across 18 years of filings, most recently posting -$12.0 million for Q1 2026.

• In Q1 2026, Deferred Taxes rose 98.19% year-over-year to -$12.0 million; the TTM figure through Mar 2026 stood at -$1.5 billion (up 58.75% YoY), while the FY2025 annual figure was -$2.1 billion, down 1.47% from the prior year.
• Deferred Taxes grew to -$12.0 million in Q1 2026, from -$433.0 million in the prior quarter.
• Over the last five years, Deferred Taxes for PFE reached as high as -$12.0 million in Q1 2026 and fell as low as -$3.4 billion in Q4 2022.
• The 5-year median for Deferred Taxes is -$765.0 million (2025), against an average of -$1.0 billion.
• Annual changes were most pronounced in 2022 — Deferred Taxes tumbled 1627.27% — and 2026, when it jumped 98.19%.
• A 5-year view of Deferred Taxes shows it stood at -$3.4 billion in 2022, then soared by 45.34% to -$1.9 billion in 2023, then climbed by 8.18% to -$1.7 billion in 2024, then jumped by 74.62% to -$433.0 million in 2025, then jumped by 97.23% to -$12.0 million in 2026.
• According to Business Quant data, Deferred Taxes over the past three periods registered -$12.0 million, -$433.0 million, and -$765.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.